3Bassi AM,Ledda S,Valentini S,et al.Damaging effects of advanced glycation end-products in the murine macrophage cell line J774A. 1. Toxicol In Vitro 2002; 16(4): 339 -47.
4Li YM. Glycation ligand binding motif in lactoferrin. Implications in diabetic infection. Adv Exp Med Biol 1998 ;443:57 - 63.
5Stitt AW, Jenkins AJ, Cooper ME. Advanced glycation end products and diabetic complications. Expert Opin Investig Drugs 2002; 11(9): 1205 - 23.
6Collison KS,Parhar RS,Saleh SS,et al.RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002; 71(3): 433 -44.
7Zykova SN, Jenssen TG, Berdal M, Olsen R, Myklebust R, Seljelid R. Altered cytokine and nitric oxide secretion in vitro by macrophage from diabetic type Ⅱ-like db/db mice. Diabetes 2000;49(9): 1451 -8.
8Doxey DL, Nares S, Park B, Trieu C, Cutler CW, Iacopino AM. Diabetes-induced impairment of macrophage cytokine release in a rat model: potential role of serium lipids. Lift Sci 1998;63(13): 1127 -36.
9Miyata S,Liu BF,Shoda H.et al.Accumulation of pyrraline-modified albumin in phagecytes due to reduced degradation by lysosomal enzymes.J Biol Chem 1997 ;272(7): 4037-42.
10Wendt T, Bucciarelli L, Qu W, et al. Receptor for Advanced Glycation Endproducts (RAGE) and Vascular Inflammation: Insights into the Pathogenesis of Macrovascular Complications in Diabetes. Curr Atheroscler Rep 2002; 4(3):228 -37.
